AbbVie (ABBV) option implied volatility flat to low
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Abbvie (ABBV) PT Raised to $115 at Piper Sandler
December 15, 2020 7:44 AM ESTPiper Sandler analyst Christopher Raymond raised the price target on Abbvie (NYSE: ABBV) to $115.00 (from $110.00) while maintaining a Overweight rating following the company's franchise focused investor call. Long-term guidance was increased to $15B for FY25 Rinvoq/ Skyrizi (previously $10B, consensus: $9.413B).
Skyrizi and... More
